Brand Value Recognized: Two Kexing Biopharm Trademarks Included in Guangdong Key Trademark Protection List

Article source：Jun 24,2026View： 446

Recently, the Key Trademark Protection Committee of the Guangdong Trademark Association officially released the 2025 Guangdong Key Trademark Protection List. Two core trademarks owned by Kexing Biopharm Co., Ltd. — “Kexing Biopharm” and “SINOGEN®” — were successfully included in the list. This recognition marks an important achievement in the company’s intellectual property protection efforts and further enhances the brand value of Kexing Biopharm.

As an innovative and international biopharmaceutical company, Kexing Biopharm focuses on developing a diversified and tiered product pipeline in key therapeutic areas, including oncology, autoimmune diseases, and antiviral therapies. Among the selected trademarks, “SINOGEN®” represents the company’s flagship product, Recombinant Human Interferon α1b. As one of China’s first genetically engineered innovative drugs, the product has more than 30 years of clinical application history. Since 2019, it has maintained a leading market share for seven consecutive years, playing an important role in safeguarding public health and promoting the development of China’s biopharmaceutical industry.

The Guangdong Key Trademark Protection List is an important initiative by Guangdong Province to strengthen intellectual property protection and optimize the business environment. Trademarks included in the list undergo rigorous multi-dimensional evaluation and review procedures, with the goal of providing targeted protection for highly recognized trademarks in key industries and strategic sectors.

Kexing Biopharm places great emphasis on brand development and intellectual property protection. The company continues to increase R&D investment, strengthen its innovation technology platforms, and has established a comprehensive intellectual property protection system covering its core technologies and products.

Looking ahead, Kexing Biopharm will continue to adhere to its innovation-driven development strategy, further strengthen intellectual property protection, enhance its brand competitiveness, and build stronger brand barriers while providing patients worldwide with more high-quality biopharmaceutical products.